Paracoccidioidomycosis, unspecified
ICD-10 B41.9 is a billable code used to indicate a diagnosis of paracoccidioidomycosis, unspecified.
Paracoccidioidomycosis is a systemic fungal infection caused by the dimorphic fungus Paracoccidioides brasiliensis, primarily endemic to regions of Central and South America. The infection typically manifests in two forms: acute and chronic, with the chronic form being more prevalent. Patients may present with respiratory symptoms, skin lesions, and systemic manifestations such as fever and weight loss. The disease is particularly concerning in immunocompromised individuals, who may experience more severe symptoms and complications. Diagnosis is often made through clinical evaluation, serological tests, and histopathological examination of tissue samples. Treatment usually involves antifungal therapy, with itraconazole and sulfamethoxazole-trimethoprim being common choices. The unspecified designation indicates that the specific form or severity of the infection has not been documented, which may complicate treatment decisions and coding accuracy.
Detailed clinical history, laboratory results, and treatment plans.
Patients presenting with respiratory symptoms and systemic signs of infection.
Documentation should clearly indicate the immunocompetence of the patient and any co-morbid conditions.
Pulmonary function tests, imaging studies, and response to antifungal therapy.
Patients with chronic cough, hemoptysis, or lung nodules.
Ensure that respiratory symptoms are linked to the fungal infection in documentation.
Used when paracoccidioidomycosis is suspected and culture is needed.
Document the reason for the culture and any prior treatments.
Infectious disease specialists should ensure comprehensive documentation of clinical findings.
The primary treatment for paracoccidioidomycosis includes antifungal medications such as itraconazole and sulfamethoxazole-trimethoprim. The choice of treatment may depend on the severity of the disease and the patient's immune status.
